Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib for uncommon EGFR-mutant non-small cell lung cancer
KCT0007003Phase 2Completed
- Sponsor
- Yuhan
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Yuhan. Primary endpoint: objective response rate. Started May 2022; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0007003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007003.